Sphingosine kinase inhibitors may hold key to halting growth of s...( Penn State College of Medicine research...)

Sphingosine kinase inhibitors may hold key to halting growth of some tumors

Penn State College of Medicine researchers have identified compounds that could wipe out an enzyme responsible for tumor growth.

"These compounds our team found are the first 'drug-like' agents that have been shown to inhibit an enzyme called sphingosine kinase," said Charles D. Smith, Ph.D., professor of pharmacology, and director of the Drug Discovery Core, Penn State College of Medicine. "Since sphingosine kinase is involved in growth regulation and certain other biological processes that are important in tumor growth, these compounds have potential use for the treatment of many types of cancer."

This study, titled, "Discovery and evaluation of inhibitors of human sphingosine kinase," appeared in the Sept. 15 issue of Cancer Research and was recently presented at two international scientific meetings. Smith's research team in the Department of Pharmacology included: Kevin J. French, Ph.D., Randy Schrecengost, Brian D. Lee, Yan Zhuang, Ph.D., Staci N. Smith, Justin L. Eberly, and Jong K. Yun, Ph.D., of the Jake Gittlen Cancer Research Institute.

Previous studies have shown that sphingosine kinase (SK) plays a pivotal role in regulating cell growth. Cell membranes contain sphingomyelin, a precursor of two lipids: ceramide, which causes programmed cell death (apoptosis), and sphingosine 1-phosphate (S1P), which causes cell proliferation. The balance of ceramide and S1P determine whether cells multiply or die.

A chain reaction with other enzymes can turn ceramide into sphingosine, which then reacts with SK to form S1P. This promotes cell proliferation, and stops the programmed cell death that would otherwise rid the body of the cancer cells. This study aimed to find a way to stop that chain reaction and create an effective option to treat cancer.

In this project, the Smith team first determined that the amount of mRNA for SK is significantly higher in tumor cells than it is in healthy cells. mRNA is genetic material that holds the informat
'"/>

Contact: Valerie Gliem
vgliem@psu.edu
814-865-9481
Penn State
15-Sep-2003

Page: 1 2
Related medicine news :

1. Researchers identify leukemia-linked pathway targeted by a new kinase inhibitor
2. COX-2 inhibitors associated with blood pressure elevation
3. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
4. Penn researchers add more evidence to demonstrate role of COX inhibitors in heart-disease risk
5. Special JAMA commentary on lessons learned from troubles with COX-2 inhibitors
6. Breast cancer may be uniquely sensitive to inhibitors of PI3K pathway
7. Aromatase inhibitors should be first-line treatment for certain type of breast cancer
8. Researchers debate recreational use of PDE-5 inhibitors
9. ACE inhibitors not needed for many heart disease patients, according to new study
10. HIV-1 protease inhibitors: Effective against malaria?
11. Mechanism found that protects aggressive melanoma from angiogenesis inhibitors

Post Your Comments: